Ashurst advises British Patient Capital on investment in EpilepsyGTx's Series A fundraising round
23 December 2025
Global law firm Ashurst has advised British Patient Capital on its investment as part of Epilepsy GTX's $33 million Series A Funding Round.
Epilepsy GTX is a biotechnology company focused on research and development of cutting-edge gene therapies to treat refractory epilepsy.
The Ashurst team was led by corporate partner Jacob Gold and senior associate Dillon Fuzi, with support from associate Elnaz Cadogan.
Ashurst has advised British Patient Capital on a number of investments in growth business in the UK life sciences sector over recent years, including its participation in funding rounds for Purespring Therapeutics, Phagenesis and Epsilogen, among others.
